Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of “Moderate Buy” by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $82.2857.

Several research firms recently weighed in on TARS. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective on the stock. Zacks Research raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th.

Insider Buying and Selling

In related news, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the sale, the insider directly owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares in the company, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC lifted its stake in shares of Tarsus Pharmaceuticals by 5.5% during the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock worth $154,790,000 after buying an additional 136,582 shares during the last quarter. TFG Asset Management GP Ltd raised its holdings in Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after acquiring an additional 71,530 shares during the period. Capricorn Fund Managers Ltd bought a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at about $14,264,000. TimesSquare Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $15,898,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth approximately $227,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $66.61 on Friday. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -32.98, a PEG ratio of 0.96 and a beta of 0.57. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25. The stock’s fifty day simple moving average is $72.54 and its 200 day simple moving average is $67.82. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.